Hydroxyprogesterone heptanoate
| Clinical data | |
|---|---|
| Trade names | H.O.P, Hydroxyprogesterone, Lutogil A.P., Lutogyl A.P., others |
| Other names | OHPH; Hydroxyprogesterone enanthate; OHPE; 17α-Hydroxyprogesterone heptanoate; 17α-Hydroxyprogesterone heptylate; 17α-Hydroxypregn-4-ene-3,20-dione 17α-heptanoate; 17α-Heptyloylpregn-4-ene-3,20-dione |
| Routes of administration | Intramuscular injection |
| Drug class | Progestogen; Progestin; Progestogen ester |
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.022.724 |
| Chemical and physical data | |
| Formula | C28H42O4 |
| Molar mass | 442.640 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications.[1][2][3][4] It has been formulated both alone and in together with estrogens, androgens/anabolic steroids, and other progestogens in several combination preparations (brand names Tocogestan, Trioestrine Retard, and Triormon Depositum).[4][5][6][7][8][9][10] OHPH is given by injection into muscle at regular intervals.[11][9]
OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[12][13][14] It appears to have similar pharmacology to that of the closely related medication hydroxyprogesterone caproate (OHPC).[15][16][17]
OHPH was first described by 1954[16] and was introduced for medical use by 1957.[6] It has been used clinically in France and Monaco in the past but is no longer marketed.[2][3][4]
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 665–. ISBN 978-1-4757-2085-3.
- ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 532–. ISBN 978-3-88763-075-1.
- ^ a b Muller NF, Dessing RP (19 June 1998). European Drug Index: European Drug Registrations (Fourth ed.). CRC Press. pp. 612–. ISBN 978-3-7692-2114-5.
- ^ a b c Kleemann A, Engel J (2001). Pharmaceutical Substances: Syntheses, Patents, Applications. Thieme. p. 1033. ISBN 978-3-13-558404-1.
- ^ Cite error: The named reference
SascoGendre1998was invoked but never defined (see the help page). - ^ a b Cite error: The named reference
ErmigliaValli1957was invoked but never defined (see the help page). - ^ Cite error: The named reference
Bordier1963was invoked but never defined (see the help page). - ^ Cite error: The named reference
ExcerptaMedica1981was invoked but never defined (see the help page). - ^ a b Cite error: The named reference
ScholarlyEditions2013was invoked but never defined (see the help page). - ^ Cite error: The named reference
Frigerio1981was invoked but never defined (see the help page). - ^ Cite error: The named reference
Krówczyński1987was invoked but never defined (see the help page). - ^ Cite error: The named reference
Schindler2014was invoked but never defined (see the help page). - ^ Cite error: The named reference
BińkowskaWoroń2015was invoked but never defined (see the help page). - ^ Cite error: The named reference
PosaciSmitz2000was invoked but never defined (see the help page). - ^ Cite error: The named reference
NeumannElger1969was invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Junkmann1954was invoked but never defined (see the help page). - ^ Cite error: The named reference
Junkmann1959was invoked but never defined (see the help page).